ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study.
<p><strong>INTRODUCTION:</strong> In this study (PRECISE), we assess the clinical utility of a germline DNA sequencing-based test (ToxNav) for mutations in DPYD and ENOSF1 genes to alter clinician-prescribed fluoropyrimidine doses and the use of a digital application (PROMinet) to...
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Publié: |
Wiley
2019
|
| _version_ | 1826288756713324544 |
|---|---|
| author | Lee, L Starkey, T Sivakumar, S Fotheringham, S Mozolowski, G Shearwood, V Palles, C Camilleri, P Church, D Kerr, R Kerr, D |
| author_facet | Lee, L Starkey, T Sivakumar, S Fotheringham, S Mozolowski, G Shearwood, V Palles, C Camilleri, P Church, D Kerr, R Kerr, D |
| author_sort | Lee, L |
| collection | OXFORD |
| description | <p><strong>INTRODUCTION:</strong> In this study (PRECISE), we assess the clinical utility of a germline DNA sequencing-based test (ToxNav) for mutations in DPYD and ENOSF1 genes to alter clinician-prescribed fluoropyrimidine doses and the use of a digital application (PROMinet) to record patient-reported chemotherapy toxicity.</p> <p><strong>MATERIALS AND METHODS:</strong> Adult patients with a histological diagnosis of colorectal cancer (CRC) who consented to fluoropyrimidine-based chemotherapy were recruited prospectively and given a digital application to monitor and record associated toxicities. Patient samples were analyzed for 18 germline coding variants in DPYD and 1 ENOSF1 variant.</p> <p><strong>RESULTS:</strong> Genetic testing was performed for 60 patients and identified one patient at increased risk of fluoropyrimidine-based toxicities. Uptake of genetic testing was high and results were available on average 17 days from initial clinical encounter. Patient-reported chemotherapy toxicity identified differences in 5-fluorouracil vs capecitabine regime profiles and identified profiles associated with subsequent need for chemotherapy dose reduction and hospital admission.</p> <p><strong>DISCUSSION:</strong> The PRECISE clinical trial demonstrated that a germline DNA sequencing-based test can provide clinically relevant information to alter clinicians' fluoropyrimidine prescription. The study also obtained high volume, high granularity patient-reported toxicity data that might allow the improvement and personalization of chemotherapy management.</p> |
| first_indexed | 2024-03-07T02:18:31Z |
| format | Conference item |
| id | oxford-uuid:a3182d3f-fa83-4a3e-af1d-433fd0ab8b9b |
| institution | University of Oxford |
| last_indexed | 2024-03-07T02:18:31Z |
| publishDate | 2019 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:a3182d3f-fa83-4a3e-af1d-433fd0ab8b9b2022-03-27T02:24:30ZToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:a3182d3f-fa83-4a3e-af1d-433fd0ab8b9bSymplectic Elements at OxfordWiley2019Lee, LStarkey, TSivakumar, SFotheringham, SMozolowski, GShearwood, VPalles, CCamilleri, PChurch, DKerr, RKerr, D<p><strong>INTRODUCTION:</strong> In this study (PRECISE), we assess the clinical utility of a germline DNA sequencing-based test (ToxNav) for mutations in DPYD and ENOSF1 genes to alter clinician-prescribed fluoropyrimidine doses and the use of a digital application (PROMinet) to record patient-reported chemotherapy toxicity.</p> <p><strong>MATERIALS AND METHODS:</strong> Adult patients with a histological diagnosis of colorectal cancer (CRC) who consented to fluoropyrimidine-based chemotherapy were recruited prospectively and given a digital application to monitor and record associated toxicities. Patient samples were analyzed for 18 germline coding variants in DPYD and 1 ENOSF1 variant.</p> <p><strong>RESULTS:</strong> Genetic testing was performed for 60 patients and identified one patient at increased risk of fluoropyrimidine-based toxicities. Uptake of genetic testing was high and results were available on average 17 days from initial clinical encounter. Patient-reported chemotherapy toxicity identified differences in 5-fluorouracil vs capecitabine regime profiles and identified profiles associated with subsequent need for chemotherapy dose reduction and hospital admission.</p> <p><strong>DISCUSSION:</strong> The PRECISE clinical trial demonstrated that a germline DNA sequencing-based test can provide clinically relevant information to alter clinicians' fluoropyrimidine prescription. The study also obtained high volume, high granularity patient-reported toxicity data that might allow the improvement and personalization of chemotherapy management.</p> |
| spellingShingle | Lee, L Starkey, T Sivakumar, S Fotheringham, S Mozolowski, G Shearwood, V Palles, C Camilleri, P Church, D Kerr, R Kerr, D ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study. |
| title | ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study. |
| title_full | ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study. |
| title_fullStr | ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study. |
| title_full_unstemmed | ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study. |
| title_short | ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study. |
| title_sort | toxnav germline genetic testing and prominet digital mobile application toxicity monitoring results of a prospective single center clinical utility study precise study |
| work_keys_str_mv | AT leel toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT starkeyt toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT sivakumars toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT fotheringhams toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT mozolowskig toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT shearwoodv toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT pallesc toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT camillerip toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT churchd toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT kerrr toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy AT kerrd toxnavgermlinegenetictestingandprominetdigitalmobileapplicationtoxicitymonitoringresultsofaprospectivesinglecenterclinicalutilitystudyprecisestudy |